18-Nov-2026 11:15:26

ORCHPHARMAGeneral news

ORCHID PHARMA Q2 FY27 CONCALL: TARGETS 3–4 ADDITIONAL XBLYCEF LICENSING DEALS IN NEXT 2 QUARTERS; EXPECTS CEFIDEROCOL INDIA LAUNCH BY SEPTEMBER–OCTOBER 2027, 7ACA COMMERCIALIZATION BY MARCH 2027 & GROSS MARGINS ABOVE 35%

ORCHID PHARMA LIMITED

← Back to feed